Vered Stearns

24.5k total citations · 6 hit papers
327 papers, 14.0k citations indexed

About

Vered Stearns is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Vered Stearns has authored 327 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 124 papers in Genetics and 117 papers in Cancer Research. Recurrent topics in Vered Stearns's work include Estrogen and related hormone effects (111 papers), Breast Cancer Treatment Studies (85 papers) and Cancer Treatment and Pharmacology (59 papers). Vered Stearns is often cited by papers focused on Estrogen and related hormone effects (111 papers), Breast Cancer Treatment Studies (85 papers) and Cancer Treatment and Pharmacology (59 papers). Vered Stearns collaborates with scholars based in United States, Canada and France. Vered Stearns's co-authors include Daniel F. Hayes, Nancy E. Davidson, David A. Flockhart, Claudine Isaacs, N. Lynn Henry, Eric P. Winer, Antonio C. Wolff, Clifford A. Hudis, Anna Maria Storniolo and Harold J. Burstein and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Vered Stearns

316 papers receiving 13.6k citations

Hit Papers

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabo... 2003 2026 2010 2018 2005 2003 2010 2014 2006 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
    2005 681 citations Zeruesenay Desta, Vered Stearns et al. profile →
  2. Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
    2003 624 citations Vered Stearns profile →
  3. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
    2010 612 citations Harold J. Burstein, Holly Anderson et al. Journal of Clinical Oncology profile →
  4. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
    2014 559 citations Harold J. Burstein, Holly Anderson et al. Journal of Clinical Oncology profile →
  5. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
    2006 548 citations Vered Stearns et al. Journal of Clinical Oncology profile →
  6. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
    2018 411 citations Harold J. Burstein, Christina Lacchetti et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vered Stearns United States 57 6.6k 4.6k 4.3k 2.9k 2.1k 327 14.0k
Victor G. Vogel United States 49 8.0k 1.2× 6.7k 1.5× 5.5k 1.3× 2.4k 0.8× 1.9k 0.9× 173 16.1k
Leslie G. Ford United States 32 4.3k 0.7× 4.8k 1.1× 3.5k 0.8× 2.6k 0.9× 3.7k 1.7× 74 13.2k
Patrick Neven Belgium 57 8.6k 1.3× 3.1k 0.7× 4.5k 1.0× 2.8k 1.0× 5.0k 2.3× 493 15.7k
Christine B. Ambrosone United States 64 5.8k 0.9× 3.2k 0.7× 4.1k 1.0× 7.0k 2.5× 1.2k 0.6× 383 16.5k
James N. Atkins United States 47 8.3k 1.3× 3.9k 0.8× 4.4k 1.0× 2.6k 0.9× 3.8k 1.8× 107 14.4k
James N. Ingle United States 74 13.9k 2.1× 7.9k 1.7× 9.4k 2.2× 5.6k 2.0× 4.0k 1.9× 365 23.6k
Timothy R. Rebbeck United States 56 3.7k 0.6× 5.6k 1.2× 2.7k 0.6× 3.0k 1.1× 2.0k 0.9× 257 12.7k
Richard J. Santen United States 78 5.2k 0.8× 10.2k 2.2× 2.9k 0.7× 6.1k 2.1× 2.1k 1.0× 355 19.6k
Paul E. Goss United States 47 5.4k 0.8× 3.7k 0.8× 3.8k 0.9× 2.3k 0.8× 2.1k 1.0× 214 10.6k
Howard L. McLeod United States 81 10.1k 1.5× 3.1k 0.7× 2.9k 0.7× 9.6k 3.3× 2.6k 1.2× 481 26.6k

Countries citing papers authored by Vered Stearns

Since Specialization
Citations

This map shows the geographic impact of Vered Stearns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vered Stearns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vered Stearns more than expected).

Fields of papers citing papers by Vered Stearns

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vered Stearns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vered Stearns. The network helps show where Vered Stearns may publish in the future.

Co-authorship network of co-authors of Vered Stearns

This figure shows the co-authorship network connecting the top 25 collaborators of Vered Stearns. A scholar is included among the top collaborators of Vered Stearns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vered Stearns. Vered Stearns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gatsonis, Constantine, Heather A. Jacene, Roisín M. Connolly, et al.. (2024). Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.. Journal of Clinical Oncology. 42(16_suppl). TPS614–TPS614.
2.
3.
Stearns, Vered, et al.. (2022). The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. Expert Opinion on Therapeutic Targets. 26(12). 1041–1056. 12 indexed citations
4.
Koh, Siang‐Boon, Kenneth N. Ross, Steven J. Isakoff, et al.. (2021). RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research. 27(17). 4883–4897. 16 indexed citations
5.
Walsh, Elaine M., John H. Fetting, Deborah K. Armstrong, et al.. (2021). Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer. 22(4). 319–325. 8 indexed citations
6.
Telli, Melinda L., Charles C. Chu, Sunil Badve, et al.. (2019). Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research. 26(11). 2704–2710. 23 indexed citations
7.
Burstein, Harold J., Christina Lacchetti, Holly Anderson, et al.. (2018). Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 37(5). 423–438. 411 indexed citations breakdown →
8.
Lee, Oukseub, Richard E. Heinz, David Ivancic, et al.. (2018). Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation. Cancer Prevention Research. 11(9). 557–568. 4 indexed citations
9.
Merino, Vanessa F., Nguyen Nguyen, Kideok Jin, et al.. (2016). Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. Cancer Research. 76(7). 2013–2024. 37 indexed citations
10.
Ingle, James N., Fang Xie, Matthew J. Ellis, et al.. (2016). Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research. 76(23). 7012–7023. 43 indexed citations
11.
Stearns, Vered, Mary Jo Fackler, Zoila A. Lopez‐Bujanda, et al.. (2016). Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. Cancer Prevention Research. 9(8). 673–682. 7 indexed citations
12.
Santa‐Maria, Cesar A., Amanda L. Blackford, Anne Nguyen, et al.. (2015). Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clinical Cancer Research. 22(6). 1395–1402. 18 indexed citations
13.
Korangath, Preethi, Wei Wen Teo, Helen Sadik, et al.. (2015). Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clinical Cancer Research. 21(14). 3263–3273. 133 indexed citations
14.
Stearns, Vered, Lisa K. Jacobs, Theodore N. Tsangaris, et al.. (2013). Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clinical Cancer Research. 19(14). 4008–4016. 24 indexed citations
15.
Henry, N. Lynn, Rong Xia, Mousumi Banerjee, et al.. (2013). Predictors of recovery of ovarian function during aromatase inhibitor therapy. Annals of Oncology. 24(8). 2011–2016. 35 indexed citations
16.
Henry, N. Lynn, Faouzi Azzouz, Zereunesay Desta, et al.. (2012). Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer. Journal of Clinical Oncology. 30(9). 936–942. 284 indexed citations
17.
Zellars, Richard C., Deborah A. Frassica, Vered Stearns, et al.. (2007). Phase I/II Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early Stage Breast Cancer: Report of Skin Toxicity and Cosmetic Outcome. International Journal of Radiation Oncology*Biology*Physics. 69(3). S26–S26. 2 indexed citations
18.
Nguyen, Anne, Vered Stearns, Anne F. Schott, et al.. (2007). Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clinical Pharmacology & Therapeutics. 83(5). 702–710. 31 indexed citations
19.
Stearns, Vered, Rebecca Slack, Nancy Greep, et al.. (2005). Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial. Journal of Clinical Oncology. 23(28). 6919–6930. 163 indexed citations
20.
Flockhart, David A., et al.. (2001). Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner. Clinical Pharmacology & Therapeutics. 69(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victor G. Vogel Breakdown of academic impact, for papers by Leslie G. Ford Breakdown of academic impact, for papers by Patrick Neven Breakdown of academic impact, for papers by Christine B. Ambrosone Breakdown of academic impact, for papers by James N. Atkins Breakdown of academic impact, for papers by James N. Ingle Breakdown of academic impact, for papers by Timothy R. Rebbeck Breakdown of academic impact, for papers by Richard J. Santen Breakdown of academic impact, for papers by Paul E. Goss Breakdown of academic impact, for papers by Howard L. McLeod
Rankless by CCL
2026